AKTIP and acute myeloid leukemia: Interestingly, the genes that were altered by FTS and rapamycin in the TSC2-deficient 621.102 AML cells were not affected by those treatments in the TSC2-re-expressing 621.103 cells, indicating that the treatments were selective for the TSC2-deficient cells only (Figure 4).